152 reports of this reaction
1.9% of all NORGESTIMATE AND ETHINYL ESTRADIOL reports
#10 most reported adverse reaction
RASH is the #10 most commonly reported adverse reaction for NORGESTIMATE AND ETHINYL ESTRADIOL, manufactured by Teva Pharmaceuticals USA, Inc.. There are 152 FDA adverse event reports linking NORGESTIMATE AND ETHINYL ESTRADIOL to RASH. This represents approximately 1.9% of all 7,959 adverse event reports for this drug.
Patients taking NORGESTIMATE AND ETHINYL ESTRADIOL who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for NORGESTIMATE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for NORGESTIMATE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 152 FDA reports for NORGESTIMATE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 1.9% of all adverse event reports for NORGESTIMATE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience rash while taking NORGESTIMATE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.